Literature DB >> 22977411

Clopidogrel versus Other Antiplatelet Agents in the Secondary Prevention of Vascular Events in Adults with Cerebrovascular Disease: Clinical and Cost-Effectiveness Analyses.

.   

Abstract

Entities:  

Year:  2010        PMID： 22977411      PMCID： PMC3411156     

Source DB:  PubMed          Journal:  CADTH Technol Overv        ISSN： 1203-9012


× No keyword cloud information.
  35 in total

1.  Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications.

Authors:  Kam-Chuen Lai; Kent-Man Chu; Wai-Mo Hui; Benjamin Chun-Yu Wong; Wai-Ka Hung; Ching-Kong Loo; Wayne Hsing-Ching Hu; Annie On-On Chan; Ka-Fai Kwok; Tang-Tat Fung; John Wong; Shiu-Kum Lam
Journal:  Clin Gastroenterol Hepatol       Date:  2006-06-22       Impact factor: 11.382

2.  Ticlopidine versus aspirin for stroke prevention: On-treatment results from the ticlopidine aspirin stroke study.

Authors: 
Journal:  J Stroke Cerebrovasc Dis       Date:  2010-06-09       Impact factor: 2.136

3.  Design of ESPRIT: an international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group.

Authors:  E L De Schryver
Journal:  Cerebrovasc Dis       Date:  2000 Mar-Apr       Impact factor: 2.762

4.  Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.

Authors:  Francis K L Chan; Jessica Y L Ching; Lawrence C T Hung; Vincent W S Wong; Vincent K S Leung; Nelson N S Kung; Aric J Hui; Justin C Y Wu; Wai K Leung; Vivian W Y Lee; Kenneth K C Lee; Yuk T Lee; James Y W Lau; Ka F To; Henry L Y Chan; S C Sydney Chung; Joseph J Y Sung
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

5.  The effect of ticlopidine on TIA compared with aspirin: a double-blind, twelve-month follow-up study.

Authors:  H Tohgi
Journal:  Agents Actions Suppl       Date:  1984

6.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

7.  Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Gregory W Albers; Pierre Amarenco; J Donald Easton; Ralph L Sacco; Philip Teal
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

8.  Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study.

Authors:  A Bellavance
Journal:  Stroke       Date:  1993-10       Impact factor: 7.914

9.  Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.

Authors:  Ralph L Sacco; Hans-Christoph Diener; Salim Yusuf; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam Vandermaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

10.  Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.

Authors:  Hans-Christoph Diener; Julien Bogousslavsky; Lawrence M Brass; Claudio Cimminiello; Laszlo Csiba; Markku Kaste; Didier Leys; Jordi Matias-Guiu; Hans-Jürgen Rupprecht
Journal:  Cerebrovasc Dis       Date:  2004-02-23       Impact factor: 2.762
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.